NASDAQ$MRNA
Moderna Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported third quarter results with revenue of $1.8 billion and a net loss of $3.6 billion, while resizing manufacturing capacity and advancing its pipeline.
Moderna reported third quarter 2023 revenues of $1.8 billion, primarily from Spikevax sales. The company experienced a net loss of $3.6 billion, mainly due to non-cash charges related to manufacturing resizing and tax valuation allowances. Moderna is preparing for multiple product launches through 2025 and expects to return to sales growth in 2025, aiming to break even in 2026.
- Third quarter revenues reached $1.8 billion, with Spikevax sales accounting for the majority.
- The company expects 2023 revenues to be at least $6 billion and anticipates approximately $4 billion in 2024.
- Net loss for the quarter was $3.6 billion, influenced by resizing charges and tax allowances.
- Moderna anticipates returning to growth in 2025 and breaking even in 2026 through product launches and disciplined investment.
Headline financials
Revenue & EPS history
Moderna · Revenue · Quarterly
$1.83B
Revenue by segment
Moderna · $1.93B total across 2 segments · Q3 2023
- Net Product Sales$1.76B—91.0%
- Other Revenue$174M—9.0%
Forward guidance
Moderna projects at least $6 billion in product sales for 2023 and approximately $4 billion in 2024, primarily driven by COVID-19 vaccine sales and the launch of its RSV vaccine. The company anticipates a return to organic sales growth in 2025 and aims to break even in 2026.
Tailwinds
- Expects product sales of at least $6 billion for 2023.
- Projects approximately $4 billion in sales in 2024.
- Anticipates returning to organic sales growth in 2025.
- Expects to break even in 2026 through product launches and disciplined investments.
- Current balance sheet is sufficient to fund planned investments without raising additional equity.
Headwinds
- Anticipates full-year tax expense of approximately $0.8 billion to $1.0 billion.
- The estimate assumes trends consistent with the fall 2022 period.
- Write-downs/charges are expected to be less than 10% of sales in 2024 and beyond.
- R&D expenses are expected to be approximately $4.5 billion in 2024 and flat to down in 2025.
- SG&A expenses are expected to be approximately $1.3 billion in 2024 and flat to down in 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.8%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+8.2%
Avg return
30 days after
59%
17 / 29 earnings
Positive
+21.0%
Q1 2020
Best reaction
-31.5%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +6.2% | +2.7% | |
| Q4 2025 | +5.3% | +16.2% | +31.0% | |
| Q3 2025 | +2.6% | +12.1% | +17.6% | |
| Q1 2025 | -5.3% | -14.4% | -6.9% | |
| Q4 2024 | +3.4% | +12.5% | +8.5% | |
| Q3 2024 | -9.6% | -16.1% | -14.2% | |
| Q2 2024 | -27.4% | -31.0% | -35.1% | |
| Q1 2024 | +12.1% | +8.6% | +27.9% | |
| Q4 2023 | +10.1% | +9.8% | +20.4% | |
| Q3 2023 | +1.7% | -3.3% | +4.8% | |
| Q2 2023 | -1.8% | -9.5% | +2.1% | |
| Q1 2023 | +5.3% | +2.8% | +0.3% | |
| Q4 2022 | -12.0% | -12.2% | -4.6% | |
| Q3 2022 | +6.6% | +10.8% | +22.7% | |
| Q2 2022 | +20.8% | +13.8% | -13.8% | |
| Q1 2022 | -3.1% | -7.3% | -6.4% | |
| Q4 2021 | +11.5% | +10.2% | +22.2% | |
| Q3 2021 | -31.5% | -31.5% | -11.3% | |
| Q2 2021 | -1.3% | +9.0% | -0.6% | |
| Q1 2021 | +0.2% | -2.4% | +26.5% | |
| Q4 2020 | +6.9% | +1.4% | -7.9% | |
| Q3 2020 | +2.6% | +5.1% | +93.2% | |
| Q2 2020 | -6.0% | -8.2% | -20.2% | |
| Q1 2020 | +21.0% | +27.4% | +18.9% | |
| Q4 2019 | +10.1% | +25.8% | +26.5% | |
| Q3 2019 | +3.6% | +3.0% | +12.1% | |
| Q2 2019 | +7.3% | +5.9% | +29.2% | |
| Q1 2019 | -5.3% | -0.5% | -28.6% | |
| Q4 2018 | -3.6% | -4.4% | +21.5% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro